IMPLQ — IPI Legacy Liquidation Co Share News
0.000.00%
Last trade - 00:00- $0.36m
- $0.12m
- $12.65m
Brief: Impel Pharmaceuticals Inc Received Two Written Notifications From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-CalciMedica, Natgas firms,
U.S. STOCKS ON THE MOVE-ReNew Energy, First Horizon, Block Inc
Impel Pharmaceuticals rises on smaller-than-expected Q4 loss
Brief: Impel Pharmaceuticals Announces Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Brief: Impel Pharmaceuticals Chief Financial & Business Officer Resigns
Brief: Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus On Maximizing Trudhesa® Commercial Opportunity
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Impel Pharmaceuticals falls after Wedbush downgrades, slashes PT
Impel Pharmaceuticals rating cut by Wedbush
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Brief: Impel Pharmaceuticals Inc - QTRLY Net Losses Were $31.1 Mln Or $1.31 Per Common Share
Brief: Impel Pharmaceuticals reports Q2 results
Brief: Impel Says First Patient Dosed In Phase 2A Study Evaluating INP105
Brief: Impel Pharmaceuticals Files Mixed Shelf Of Up To $200 Million
Brief: Impel Pharmaceuticals Announces First Quarter 2022 Financial Results
Brief: Impel Neuropharma Announces Company Will Now Be Known As Impel Pharmaceuticals
Guggenheim optimistic about Impel NeuroPharma's migraine drug uptake
Brief: Impel Neuropharma Reports Q4 Non-GAAP Loss Per Share $1.07